Mirena® is an intrauterine device (IUD) designed to release the hormone levonorgestrel, a type of progesterone, to prevent unwanted pregnancy. The device is implanted into the patient’s uterus where it releases these hormones for up to five years. The device is marketed as a way to prevent pregnancy for up to five years without the need to take a pill or utilize other traditional birth control methods. Unfortunately, patients who are implanted with Mirena® may be at a higher risk of serious injuries or complications than patients using other forms of birth control.
The history of Mirena® litigation is a complicated one. The United States Judicial Panel on Multidistrict Litigation originally created MDL No. 2434, which was centralized in the Southern District of New York but was limited to only cases alleging migration of Mirena® into the uterus of patients. MDL 2434 did not include claims that Mirena® caused Intracranial hypertension. In July 2016, the presiding judge of MDL 2434 entered an Order granting summary judgment to Defendants in all cases in the MDL, effectively eliminating the litigation. That ruling is currently on appeal.
In April 2017, the United States Judicial Panel on Multidistrict Litigation created MDL No. 2767 and centralized the MDL in the Southern District of New York in front of Presiding Judge Paul A. Engelmayer. Unlike the first MDL concerning Mirena®, the second Mirena MDL is focused solely on alleged intracranial hypertension injuries. As a result of the creation of this MDL, every lawsuit filed in any Federal Court in the U.S. alleging intracranial hypertension injuries caused by Mirena® will be transferred into the MDL for pretrial proceedings.